CLINICAL TRIALS PROFILE FOR CORTISONE ACETATE

All Clinical Trials for CORTISONE ACETATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00489840 ↗	Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate	Completed	Alcon Research	Phase 1/Phase 2	2007-05-01	Investigation to evaluate Anecortave Acetate in the treatment of chronic central serous chorioretinopathy
NCT00489840 ↗	Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate	Completed	LuEsther T. Mertz Retinal Research Center	Phase 1/Phase 2	2007-05-01	Investigation to evaluate Anecortave Acetate in the treatment of chronic central serous chorioretinopathy
NCT00489840 ↗	Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate	Completed	Manhattan Eye, Ear & Throat Hospital	Phase 1/Phase 2	2007-05-01	Investigation to evaluate Anecortave Acetate in the treatment of chronic central serous chorioretinopathy
NCT00915343 ↗	Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency	Completed	Shire	Phase 2/Phase 3	2007-08-21	This is a randomised, controlled, open, two-armed, two-period cross-over, multi-centre phase II/III study to assess the safety, tolerability and pharmacokinetics of once-daily oral modified-release hydrocortisone in comparison to conventional thrice-daily oral hydrocortisone tablets in patients with adrenal insufficiency
NCT01771328 ↗	Continuous Subcutaneous Hydrocortisone Infusion in Congenital Adrenal Hyperplasia	Unknown status	Haukeland University Hospital	Phase 2	2013-02-01	The conventional glucocorticoid replacement therapy in congenital adrenal hyperplasia (CAH) renders the cortisol levels unphysiological, which may cause symptoms and long-term complications. Glucocorticoid replacement is technically feasible by continuous subcutaneous hydrocortisone infusion (CSHI), and can mimic the normal diurnal cortisol rhythm. This method was recently applied to treat a patient through a critical phase of puberty. This is a clinical trial aiming to evaluate CSHI treatment in patients with CAH. The main objective is to determine the effects of CSHI on metabolic parameters (androstenedione and 17-hydroxyprogesterone profiles, and testosterone,adrenocorticotropic hormone(ACTH), cortisol, and bone markers), and to determine the required glucocorticoid doses. Secondary objectives are to determine effects on clinical status, body weight, blood pressure and other metabolic parameters, as well as on subjective health status (AddiQoL, SF36).

Clinical Trial Conditions for CORTISONE ACETATE

Condition Name

Condition Name for CORTISONE ACETATE
Intervention	Trials
Adrenal Insufficiency	2
Addison Disease	1
Adrenal Hyperplasia, Congenital	1
Atrial Fibrillation	1

Condition MeSH

Condition MeSH for CORTISONE ACETATE
Intervention	Trials
Adrenal Insufficiency	2
Intervertebral Disc Degeneration	1
Osteoarthritis, Knee	1
Addison Disease	1

Clinical Trial Locations for CORTISONE ACETATE

Trials by Country

Trials by Country for CORTISONE ACETATE
Location	Trials
Norway	2
Brazil	1
United States	1
Israel	1
Canada	1

Trials by US State

Trials by US State for CORTISONE ACETATE
Location	Trials
New York	1

Clinical Trial Progress for CORTISONE ACETATE

Clinical Trial Phase

Clinical Trial Phase for CORTISONE ACETATE
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	1
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for CORTISONE ACETATE
Clinical Trial Phase	Trials
Completed	4
Unknown status	3
Not yet recruiting	1

Clinical Trial Sponsors for CORTISONE ACETATE

Sponsor Name

Sponsor Name for CORTISONE ACETATE
Sponsor	Trials
Haukeland University Hospital	2
Fundação de Amparo à Pesquisa do Estado de São Paulo	1
Federal University of São Paulo	1

Sponsor Type

Sponsor Type for CORTISONE ACETATE
Sponsor	Trials
Other	12
Industry	2